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Dr Thomas Forbes (London, Ontario, Canada). With the
absence of long-term outcomes in octogenarians, the authors set
out to investigate periprocedural and long-term outcomes in these
patients compared to younger patients. Over a recent 5-year pe-
riod, they treated 320 patients, a third of which were over 80 years
of age. Not only were these patients older, but they were also
sicker, with higher degrees of coronary disease, diabetes, hyperten-
sion, COPD, and renal dysfunction.
Their 5-year outcomes were reassuring in that these patients
had similar survival compared with younger patients. From the
data presented, I am not sure what proportion of them actually had
5-year follow-up completed, given that this study took place
between 2003 and 2008. However, these results are reassuring
that these older patients appear to have sufficient life expectancy to
benefit from the prophylactic nature of elective aneurysm repair.
I have several specific questions regarding these findings. The
authors observed an early increased rate of pulmonary complica-
tions and access-site hematomas in these older patients. Could the
pulmonary complication rate be due to the use of general anesthe-
sia? If so, these older patients might benefit from the use of
regional anesthesia techniques that might limit these pulmonary
complications and length of stay.
The authors observed an increased rate of groin hematomas in
these elderly patients. This is an interesting finding. Is this a factor
of antiplatelet medication, or some technical factor? As well, why
do the authors suppose that octogenarians were more apt to have
a type II endoleak? Is this a true observation, or a factor of differing
surveillance regimens?
Dr Fonseca. As to your first question, this is pretty much in
line with EUROSTAR data, that they have looked at their periop-to have high rates of access-site hematomas, pulmonary complica-
tions. Yet, in contrast to our study, they also found worsening renal
dysfunction in the elderly population.
When analyzing our pulmonary complications in elderly pa-
tients, our institution, for the most part, uses endotracheal intuba-
tion and general anesthesia, unless there is a prohibitive risk. So
certainly those patients that had such a significantly reduced FEV1
usually undergo EVAR under spinal and regional anesthesia, but
we usually try to institute general anesthesia to ensure better
precise deployment of endografting.
In terms of access-site hematomas, we have been looking at
this and we are actually doing a retrospective analysis specifically
looking at the mode and the type of either mono or dual antiplate-
let regimen that some of those patients might have had, especially
some of the sicker, elderly patients with more extensive preopera-
tive coronary artery disease. Right now, we are still in the process of
gathering these data, but we suspect that the amount of antiplatelet
agents has something to do with it.
Something else that can explain this, although speculative, as
you become elderly, your vessels are somewhat more calcific and
might have contributed to access-site hematomas. But of all the
hematomas that were reviewed in our literature, only three of those
patients had to be taken back to the operating room for decom-
pression and washout. So that was significant.
In terms of type II endoleaks, I completely agree with you. We
are perplexed by these data. The only thing that comes to mind is
perhaps these octogenarians, and we have to basically look back at
the post-EVAR aortogram, but we suspect that perhaps these
patients have a lesser rich amount of collaterals and lumbar arteries
that are not contributing to as much as type II endoleaks. But
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elderly and younger patient cohorts were the same.
Dr David Neschis (Baltimore, Md). I have a comment to
further support your results. As you might recall, in EVAR-2, a
substantial number of patients in the repair group, in waiting to getcounted as operative deaths. In the same vein, I think it was about
27% of patients who were in the surveillance group decided they
did not want to sit around and wait until they burst. I believe they
left the study, got treated, and those patients had a 2% mortality,
not the 9% reported for the repair group. So I think your findingstheir repair, ruptured before the repair occurred. Those were are consistent and should support policy.
